Cardiovascular Toxicities of Androgen Deprivation Therapy

    Azariyas A. Challa, Adam Calaway, Jennifer Cullen, Jorge García, Nihar R. Desai, Neal L. Weintraub, Anita Deswal, Shelby Kutty, Ajay Vallakati, Daniel Addison, Ragavendra R. Baliga, Courtney Campbell, Avirup Guha
    Studysummary This review discusses cardiovascular risks associated with androgen deprivation therapy in prostate cancer patients and highlights ongoing research, including the potential reduced COVID-19 susceptibility, but reports no new results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    5 / 5 results